Alzheimers & Dementia
Scope & Guideline
Pioneering discoveries in neurodegenerative diseases.
Introduction
Aims and Scopes
- Neurobiology of Alzheimer's Disease:
Investigating the underlying biological mechanisms of Alzheimer's disease, including amyloid and tau pathology, neuroinflammation, and neurodegeneration. - Clinical and Diagnostic Biomarkers:
Development and validation of biomarkers for early detection, diagnosis, and monitoring of Alzheimer's disease progression, leveraging blood, CSF, and imaging techniques. - Treatment and Therapeutics:
Research on pharmacological and non-pharmacological interventions aimed at modifying disease progression and improving quality of life for patients. - Epidemiology and Risk Factors:
Exploring the epidemiology of Alzheimer's disease, including risk factors, prevalence, and the impact of comorbidities across diverse populations. - Socioeconomic and Behavioral Aspects:
Understanding the role of social determinants, caregiver experiences, and lifestyle factors in the context of Alzheimer's disease and dementia care. - Innovative Research Methodologies:
Utilizing cutting-edge technologies such as AI, machine learning, and multi-omics approaches to enhance research capabilities and data analysis.
Trending and Emerging
- Biomarker Development and Validation:
There is a growing emphasis on identifying and validating biomarkers for early diagnosis and progression tracking, particularly through blood-based assays and imaging techniques. - Digital Health and Technology Integration:
The integration of digital tools for cognitive assessment and monitoring, including AI and machine learning applications, is becoming increasingly significant in Alzheimer's research. - Neuroinflammation and Immune Response:
Research focusing on neuroinflammatory processes and the immune system's role in Alzheimer's disease is gaining traction, highlighting its potential for therapeutic targeting. - Lifestyle and Behavioral Interventions:
Emerging studies are exploring the impact of lifestyle modifications, such as diet and physical activity, on cognitive health and dementia risk reduction. - Longitudinal and Multi-Cohort Studies:
There is an increasing trend towards conducting long-term longitudinal studies that examine cognitive decline across diverse populations and various stages of Alzheimer's disease. - Health Disparities and Social Determinants:
Research addressing health disparities and the influence of social determinants on Alzheimer's disease prevalence and outcomes is becoming more prominent, reflecting a broader societal perspective.
Declining or Waning
- Traditional Neuropsychological Assessments:
There is a noticeable shift from reliance on traditional neuropsychological tests towards more innovative and objective measures, such as digital cognitive assessments and biomarkers. - Generalized Risk Factor Studies:
Research focusing broadly on risk factors without specific contextual application is declining in favor of studies that consider individual and population-specific variables. - Studies with Limited Diversity:
Research that does not address or include diverse populations is becoming less prevalent, as the field increasingly values inclusivity and representation in study designs. - Single-Domain Approaches:
There is a move away from single-domain studies towards integrated approaches that consider the multifactorial nature of Alzheimer's disease, including genetic, environmental, and lifestyle factors. - Basic Science without Translational Focus:
Basic science research that does not translate into clinical applications or implications is less favored, as the journal emphasizes studies that bridge the gap between laboratory findings and clinical practice.
Similar Journals
FOLIA NEUROPATHOLOGICA
Elevating neuropathology discourse globally.FOLIA NEUROPATHOLOGICA is a distinguished Open Access journal specializing in the fields of Neurology and Pathology, published by the reputable TERMEDIA PUBLISHING HOUSE LTD. With an ISSN of 1641-4640 and E-ISSN 1509-572X, this journal has been a vital resource for the dissemination of high-quality research since its inception in 1994. Covering a broad spectrum of topics within neuropathology, the journal emphasizes clinical findings and forensic implications, making it an essential platform for healthcare professionals, researchers, and students alike. With impressive impact factors positioning it in the Q3 category for both Neurology (clinical) and Pathology and Forensic Medicine, FOLIA NEUROPATHOLOGICA occupies a significant place among its peers, ranked within the 36th to 46th percentiles on Scopus. Scholars can benefit from the Open Access model implemented since 2005, ensuring wide accessibility and distribution of critical research outputs aimed at advancing both clinical practices and academic knowledge. Based in Poland, at KLEEBERGA 2, POZNAN 61-615, this journal continues to shape the discourse in neuropathology and related fields.
NEUROBIOLOGY OF AGING
Transforming Understanding of Aging Through NeurobiologyNEUROBIOLOGY OF AGING, published by Elsevier Science Inc, is a premier journal dedicated to advancing our understanding of the complex interactions between the aging process and neurobiological mechanisms. With an ISSN of 0197-4580 and E-ISSN 1558-1497, the journal has established itself as a critical resource in the fields of Aging, Developmental Biology, Geriatrics and Gerontology, Clinical Neurology, and Neuroscience. Boasting a Q1 ranking in multiple categories, the journal is positioned within the top echelons of scholarly publication, underscoring its significant impact with an impressive Scopus ranking in various subfields. Committed to disseminating high-quality, peer-reviewed research, NEUROBIOLOGY OF AGING welcomes original articles, reviews, and research notes aiming to uncover the underlying processes of aging on the nervous system, fostering collaboration among researchers, professionals, and students alike. Although primarily subscription-based, the journal continues to play a vital role in shaping the discourse on aging and neurobiology, making it an essential publication for those engaged in this dynamic field.
AGEING RESEARCH REVIEWS
Exploring the Frontiers of Age-Related ResearchAGEING RESEARCH REVIEWS, published by Elsevier Ireland Ltd, is a prestigious academic journal dedicated to advancing our understanding of the biological, psychological, and societal aspects of aging. With an ISSN of 1568-1637 and E-ISSN of 1872-9649, this journal has established itself as a leading resource in the fields of Aging, Biochemistry, Biotechnology, Molecular Biology, and Neurology, consistently ranked in the Q1 category across these disciplines as of 2023. For researchers, students, and professionals eager to explore cutting-edge findings and innovative methodologies, AGEING RESEARCH REVIEWS gathers comprehensive reviews that facilitate a deeper understanding of age-related processes. Its high impact factor and exceptional Scopus rankings—ranking #1 in Aging and #3 in Neurology—underscore its critical role in shaping contemporary aging research. This journal not only serves as a vital reference point but also fosters a collaborative space for the scientific community focused on improving health outcomes across the life span. Published continuously since 2002 and with a converging focus through 2024, AGEING RESEARCH REVIEWS remains committed to disseminating impactful knowledge that drives progress in our understanding of the aging process.
Translational Neurodegeneration
Advancing the Frontiers of Neurodegenerative ResearchTranslational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.
Degenerative Neurological and Neuromuscular Disease
Advancing knowledge in neurodegenerative research.Degenerative Neurological and Neuromuscular Disease is a distinguished academic journal published by DOVE MEDICAL PRESS LTD, focusing on the latest advancements in the field of neurology and neuromuscular disorders. With a commitment to disseminating high-quality research, the journal aims to provide a critical platform for researchers, healthcare professionals, and students to share and engage with groundbreaking studies that advance our understanding of degenerative conditions affecting the nervous system. Although the journal's impact factor and h-index are currently not available, its open access model ensures that the valuable findings published within are accessible to a global audience, thereby fostering collaboration and innovation in neurological health. The journal's address is PO BOX 300-008, Albany, Auckland 0752, New Zealand, reflecting its international relevance and commitment to advancing the field of neurology. As the understanding of neurodegenerative diseases and neuromuscular challenges continues to evolve, Degenerative Neurological and Neuromuscular Disease serves as an essential resource for anyone dedicated to improving patient outcomes and advancing scientific knowledge.
NEUROBIOLOGY OF DISEASE
Bridging Science and Therapeutics in NeurologyNEUROBIOLOGY OF DISEASE is a premier journal dedicated to advancing the understanding of neurological disorders and the underlying biological processes, published by Academic Press Inc, Elsevier Science. With an impressive impact factor indicative of its significance—ranked in the Q1 quartile in Neurology for 2023 and occupying the 14th rank out of 192 journals in the field of Neuroscience and Neurology—this journal serves as a critical resource for researchers, clinicians, and students alike. The journal has a rich history since its inception in 1994, continuously evolving its scope to encompass groundbreaking research and insights into neurobiological mechanisms and disease pathology. Though it currently does not provide Open Access options, NEUROBIOLOGY OF DISEASE remains a vital vessel for disseminating knowledge that significantly contributes to the field of neurology, fostering an understanding that can lead to innovative therapeutic strategies.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
Empowering professionals with cutting-edge findings on dementia.ALZHEIMER DISEASE & ASSOCIATED DISORDERS, published by Lippincott Williams & Wilkins, is a pivotal journal for advancing knowledge in the fields of clinical psychology, geriatric medicine, and psychiatry. With a history spanning from 1987 to 2024, this journal provides a comprehensive platform for researchers and clinicians to disseminate significant findings related to Alzheimer's disease and associated cognitive disorders. Ranked within the second and third quartiles in various categories, including clinical psychology and geriatrics, it retains a solid academic reputation, indicated by its diverse Scopus rankings, such as #137 in Clinical Psychology and #20 in Nursing & Gerontology. Although it does not offer open access, the journal is recognized for its commitment to peer-reviewed research, making it a valuable resource for professionals and students alike, aiming to stay abreast of the latest developments and evidence-based practices in Alzheimer’s and associated conditions.
NEUROPHARMACOLOGY
Charting New Territories in Neuropharmacological ScienceNEUROPHARMACOLOGY, published by PERGAMON-ELSEVIER SCIENCE LTD, is a prestigious journal in the field of neuroscience and pharmacology, with a distinguished history dating back to 1962. With an ISSN of 0028-3908 and an E-ISSN of 1873-7064, the journal serves as a dynamic platform for the latest research that explores the intricate relationships between pharmacological agents and neural processes. Positioned in the Q1 quartile in both Cellular and Molecular Neuroscience and Pharmacology, it is recognized for its significant impact in the scientific community, boasting Scopus rankings of #36 in Pharmacology and #16 in Cellular and Molecular Neuroscience, underscoring its excellence and relevance. Although not an open access publication, its contributions are pivotal for researchers, professionals, and students sought to understand the complexities of neuropharmacological interactions. The journal aims to disseminate groundbreaking research findings, reviews, and perspectives that expand the frontiers of knowledge in the fields, making it an essential resource for anyone involved in neuroscience and pharmacology research.
Neuropsychiatric Disease and Treatment
Bridging Research and Practice in NeuropsychiatryNeuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.
NEUROLOGICAL SCIENCES
Elevating knowledge in neurological sciences for a healthier tomorrow.NEUROLOGICAL SCIENCES, published by SPRINGER-VERLAG ITALIA SRL, is a premier journal that has been a cornerstone in the field of neurology and related disciplines since its inception in 1996. With an impressive Q1 ranking in Dermatology and Q2 rankings in Neuroloy (clinical) as well as Psychiatry and Mental Health, this journal consistently delivers high-quality peer-reviewed research that informs and shapes clinical practice. The journal boasts a significant presence on Scopus, positioned in the 89th percentile for Dermatology, 73rd for Psychiatry and Mental Health, and 72nd for Neurology (clinical), reflecting its influential contributions to medical knowledge. Open Access options are available, ensuring that this valuable research is accessible to a wider audience committed to advancing their understanding of neurological sciences. As it converges into future years (2024 and beyond), NEUROLOGICAL SCIENCES aims to continue foster collaboration and innovation amongst researchers, professionals, and students within the neurology and mental health domains, making it an indispensable resource for those dedicated to improving patient outcomes and advancing scholarly dialogue.